GBM Clinical Trials
Here are the 6 most popular medical studies for gbm
Histone Deacetylase Inhibitor
MRSI + RT/TMZ ± Belinostat for GBM
This trial is testing whether adding MRSI to the standard evaluation for newly diagnosed GBM patients treated with RT/TMZ can help predict better outcomes, and whether MRSI can aid in the early determination of response to this new therapy.
ATR Kinase Inhibitor
Adavosertib + Radiation + Temozolomide for Glioblastoma
This trial is studying adavosertib given with radiation therapy and temozolomide to see how well it works compared to radiation therapy and temozolomide alone in treating patients with newly diagnosed or recurrent glioblastoma.
Tyrosine Kinase Inhibitor
Lapatinib + Temozolomide + Radiation for Glioblastoma
This trial is for patients with newly diagnosed glioblastoma multiforme. The standard treatment for this cancer is radiation therapy and the chemotherapy agent Temozolomide. However, the study drug Lapatinib has not been FDA approved for use in brain tumor treatment. This study is testing to see if Lapatinib is safe and effective when given in combination with radiation therapy and Temozolomide.
Procedure
MRI-Guided Laser Ablation + Chemotherapy for Brain Cancer
This trial will use MRI and blood tests to develop a way to measure and identify when the blood brain barrier is most disrupted after treatment for brain tumors, in order to improve treatment.
Popular filter options for gbm trials
GBM Clinical Trials
View 94 GBM medical studies.
Cancer Vaccine
Dendritic Cell Vaccine for Brain Cancer
This trial is testing which combination of immunotherapy vaccines is most effective in patients with malignant glioma, a type of brain cancer. Dendritic cells, which present cell identifiers to the immune system, are isolated from the subject's blood and pulsed with tumor lysate, a combination that is hoped will stimulate the immune system to recognize and destroy the patient's brain tumor. The pulsed dendritic cells are then injected back into the patient, with or without adjuvant imiquimod or poly ICLC.
Histone Deacetylase Inhibitor
Vorinostat + Isotretinoin + Temozolomide for Glioblastoma
This trial is testing if vorinostat, given with isotretinoin and temozolomide, can help control glioblastoma or gliosarcoma. The safety of the drug combination will also be studied.
Dendritic cell immunotherapy
Immunotherapy with DCVax-L for Brain Cancer
This trial is testing a new therapy, DCVax-L, for patients with newly diagnosed Glioblastoma (GBM) who are scheduled for surgery. The patients will receive the standard of care, including radiation and Temodar therapy, and then will be randomly assigned to also receive either DCVax-L or a placebo. All patients will have the option to receive DCVax-L after their disease progresses.
Gliosarcoma Clinical Trials
View 31 Gliosarcoma medical studies.
Dendritic cell immunotherapy
Immunotherapy with DCVax-L for Brain Cancer
This trial is testing a new therapy, DCVax-L, for patients with newly diagnosed Glioblastoma (GBM) who are scheduled for surgery. The patients will receive the standard of care, including radiation and Temodar therapy, and then will be randomly assigned to also receive either DCVax-L or a placebo. All patients will have the option to receive DCVax-L after their disease progresses.
Tyrosine Kinase Inhibitor
Lapatinib Before Surgery for Brain Tumor
This trial is testing how well lapatinib ditosylate works in treating patients with high-grade glioma that has come back. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
MGMT Positive Clinical Trials
View 10 MGMT positive medical studies.
Alkylating agent
Tinostamustine + Radiation Therapy for Glioblastoma
This trial is studying the side effects and best dose of a drug called tinostamustine, given with or without radiation therapy, in treating patients with newly diagnosed glioblastoma that does not have a gene mutation called MGMT-unmethylated. Tinostamustine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
MET Positive Clinical Trials
View 9 MET positive medical studies.
Cancer Vaccine
Personalized Cancer Vaccine + RT + Pembrolizumab for Glioblastoma
This trial is studying a new type of vaccine as a possible treatment for patients with glioblastoma. It is evaluating the safety of the vaccine and finding the right dose to use.
Alkylating agents
Pembrolizumab + Temozolomide + TTFields for Glioblastoma
This trial is testing whether adding pembrolizumab to the standard treatment for glioblastoma (surgery, radiation, and chemotherapy) can help patients live longer without their disease progressing.
IDO1 Inhibitor
Immunotherapy + Targeted Therapy + Radiation for Glioblastoma
This trial is testing a combination of immunotherapy and targeted therapy with radiation therapy, with or without chemotherapy, to see if it is more effective than standard radiation therapy with or without chemotherapy in treating patients with newly diagnosed glioblastoma.
Glioblastoma Clinical Trials With No Placebo
View 96 glioblastoma medical studies that do not have a placebo group.
Cancer Vaccine
Dendritic Cell Vaccine for Brain Cancer
This trial is testing which combination of immunotherapy vaccines is most effective in patients with malignant glioma, a type of brain cancer. Dendritic cells, which present cell identifiers to the immune system, are isolated from the subject's blood and pulsed with tumor lysate, a combination that is hoped will stimulate the immune system to recognize and destroy the patient's brain tumor. The pulsed dendritic cells are then injected back into the patient, with or without adjuvant imiquimod or poly ICLC.
CAR T-cell Therapy
Immunotherapy with TIL for Cancer
This trial is testing a new experimental therapy to see if it can cause tumors to shrink in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. The therapy involves taking white blood cells from patients' tumors, growing them in the laboratory, and then giving the cells back to the patient.
Histone Deacetylase Inhibitor
Vorinostat + Isotretinoin + Temozolomide for Glioblastoma
This trial is testing if vorinostat, given with isotretinoin and temozolomide, can help control glioblastoma or gliosarcoma. The safety of the drug combination will also be studied.
View More Gbm Trials
See another 66 medical studies focused on gbm.
Frequently Asked Questions
Introduction to gbm
What are the top hospitals conducting gbm research?
When it comes to cutting-edge clinical trials for glioblastoma (gbm), several renowned hospitals are leading the charge. One such institution is the Dana-Farber Cancer Institute in Boston, which currently has 17 active gbm trials underway. Glioblastoma, a highly aggressive and deadly form of brain cancer, poses significant challenges for patients and researchers alike. Likewise, Washington University School of Medicine in Saint Louis is also making strides with 14 ongoing gbm trials of their own. Memorial Sloan Kettering Cancer Center in New york follows closely behind with 13 active gbm trials. These institutions bring together top medical professionals and scientists who work tirelessly to find new treatment options and improve outcomes for those affected by this devastating disease.
Meanwhile, Johns Hopkins University/Sidney Kimmel Cancer Center in Baltimore joins this league with ten ongoing clinical trials specifically focused on glioblastoma research. Last but not least, the Moffitt Cancer Center located in Tampa contributes significantly to the fight against gbm as well; they presently have nine active clinical trials dedicated solely to finding innovative solutions for this challenging condition.
While these hospitals might not yet have any completed or all-time recorded gbm trials under their belts, their commitment to pursuing groundbreaking research offers hope to patients worldwide. By pushing boundaries and exploring novel approaches through these ongoing studies, these institutions play an integral role in advancing our understanding and management of glioblastoma—a crucial step toward improved treatments and ultimately a potential cure that could transform countless lives impacted by this formidable disease.
Which are the best cities for gbm clinical trials?
When it comes to gbm clinical trials, several cities emerge as leading hubs for research and development. Boston, Massachusetts leads the pack with 56 active trials investigating treatments like Ipilimumab, Adavosertib, and others. New york, New York closely follows with 48 ongoing studies focusing on INO-5401, VAL-083, and more. Los Angeles, California is another prominent city in the field with 44 active trials exploring Veliparib and other interventions. Saint Louis, Missouri and Baltimore Maryland also contribute significantly to gbm clinical trials with 27 and 26 active studies respectively. These cities provide individuals battling glioblastoma multiforme access to cutting-edge research that may lead to groundbreaking advancements in treatment options.
Which are the top treatments for gbm being explored in clinical trials?
Glioblastoma multiforme (GBM) remains a challenging disease to treat, but ongoing clinical trials offer hope for patients. Among the top treatments being explored are:
- Temozolomide: Currently involved in 8 active GBM trials and has been widely studied with over 260 all-time trials.
- Bevacizumab: Showing promise in its role as an anti-angiogenic therapy, it is being investigated in 7 active GBM trials and has accumulated over 150 all-time studies.
- Lomustine: With involvement in 5 active GBM trials and over 130 all-time studies, this alkylating agent continues to be explored for its potential benefits. These three treatments represent some of the leading avenues of research that could potentially revolutionize the management of GBM.
What are the most recent clinical trials for gbm?
Recent clinical trials have brought new hope for patients with glioblastoma (gbm), a challenging form of brain cancer. Among these trials, NanO2TM in Phase 2 has shown promise as a potential treatment option. Another study in Phase 3 investigated the combination of radiation therapy (RT) with temozolomide (TMZ) and enzastaurin (ENZ), as well as ENZ alone or TMZ and ENZ, offering potential advancements in gbm treatment approaches. Furthermore, an innovative trial using human CMV pp65-LAMP mRNA-pulsed autologous dendritic cells aims to harness the power of immunotherapy against gbm. These recent developments offer renewed optimism for patients fighting this aggressive disease.
What gbm clinical trials were recently completed?
Recently completed clinical trials for glioblastoma (GBM), a highly aggressive form of brain cancer, have made significant strides in advancing treatment options. One notable trial focused on the investigation of Uproleselan, led by Washington University School of Medicine and concluded in October 2021. Another groundbreaking study sponsored by the National Cancer Institute examined the efficacy of mRNA-1273 and finished its research phase in September 2021. Lastly, AgenTus Therapeutics successfully completed their agenT-797 trial in January 2021. These achievements highlight the dedication of researchers to combat GBM and provide hope for patients grappling with this devastating disease.